CD8A and neoplasm: To address the limitations, we assessed the utility of this oncogenic marker in MF by quantifying TOX protein expression in skin samples from patients with plaque and tumor-stage MF stained simultaneously for CD3, CD4, and CD8 in multispectral sequential fluorescence immunohistochemistry (MSI) by comparing that data with those from healthy controls.